Osterman MT, Lichtenstein GR: Chapter 116: Ulcerative Colitis Sleisenger and Fordtran’s Gastrointestinal and Liver Disease, 10th Edition : 2023-61,2016.
Scott FI, Osterman MT: Therapeutic drug monitoring of biologic agents Biologics in Inflammatory Bowel Disease : 2016.
Gastonguay MR, Lasch K, Barocas M, Rosario M, Wilbur J, Dirks N, Osterman MT: Vedolizumab efficacy exposure-response relationship for ulcerative colitis patients (GEMINI I) based on causal inference analysis American Journal of Gastroenterology : 2016.
Osterman MT, Sandborn WJ, Colombel J-F, Peyrin-Biroulet L, Robinson AM, Zhou Q, Lewis JD: Crohn’s disease activity and concomitant immunosuppressants affect the risk of serious and opportunistic infections in patients treated with adalimumab American Journal of Gastroenterology : 2016.
Osterman MT, Roblin X, Glover S, Navaneethan U, Popa MA, Wyant T, James A, Lasch K, Rosario M: The relationship between vedolizumab drug concentrations at or before week 6 and remission at week 14 in ulcerative colitis patients from GEMINI 1 Gastroenterology 150 : S-105,2016.
Osterman MT, Lichtenstein GR: Medical treatment of perianal Crohn’s fistulae Pediatric Inflammatory Bowel Disease: Third Edition : 2016.
Chachu KA, Osterman MT: How to diagnose and treat IBD mimics in the refractory IBD patient who does not have IBD Inflammatory Bowel Diseases : 2016.
Zhang J, Xie F, Yun H, Chen L, Muntner P, Levitan EB, Safford MM, Kent ST, Osterman MT, Lewis JD, Saag K, Singh JA, Curtis JR: Comparative effects of biologics on coronary cardiovascular risk among older patients with rheumatoid arthritis Annals of the Rheumatic Diseases : 2016.
Mamtani R, Clark AS, Scott FI, Brensinger CM, Boursi B, Chen L, Xie F, Yun H, Osterman MT, Curtis JR, Lewis JD: Association between breast cancer recurrence with immunosuppression in rheumatoid arthritis and inflammatory bowel disease: a cohort study Arhritis and Rheumatology : 2016.
Vajravelu RK, Osterman MT, Aberra FN, Roy JA, Lichtenstein GR, Mamtani R, Goldberg DS, Lewis JD, Scott FI: Predictors and Clinical Impact of Indeterminate QuantiFERON-TB Gold Testing in Inflammatory Bowel Disease Pharmacoepidemiology and Drug Safety : 2016.
View all publications